ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$20.29 USD
+0.72 (3.68%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $20.22 -0.07 (-0.34%) 7:14 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.29 USD
+0.72 (3.68%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $20.22 -0.07 (-0.34%) 7:14 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Zacks News
Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the most recent trading session, Adma Biologics (ADMA) closed at $19.50, indicating a -1.37% shift from the previous trading day.
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.
Adma Biologics (ADMA) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Adma Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
by Zacks Equity Research
Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.
Adma Biologics (ADMA) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $19.44, denoting a -0.26% change from the preceding trading day.
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
by Zacks Equity Research
PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.
Adma Biologics (ADMA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $19.98, denoting a +1.22% change from the preceding trading day.
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest?
by Ekta Bagri
ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYC
Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Here's Why Momentum in Adma Biologics (ADMA) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Adma Biologics (ADMA) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
ADMA Biologics Inc (ADMA) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYX
Beat the Market Like Zacks: CareDx, Fair Isaac, 3M in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Is ADMA Biologics (ADMA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.
Is Adma Biologics (ADMA) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Here's What Could Help Adma Biologics (ADMA) Maintain Its Recent Price Strength
by Zacks Equity Research
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYX
ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?
by Ekta Bagri
The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.
Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Perspective Therapeutics (CATX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.